GlassScriptPhysician profile
Mark S Morginstin
NPI 1124000278
$710.70
in general payments reported to CMS, 2019-2025
20 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.77 · 2020: $33.89 · 2021: $11.92 · 2022: $24.86 · 2023: $36.82 · 2024: $70.29 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.78 |
| Education | $193.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $170.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $118.54 | 2019-2025 | Imfinzi, Calquence |
| Daiichi Sankyo INC. | $77.10 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $44.19 | 2020-2025 | |
| Genentech USA, INC. | $37.23 | 2019-2022 | |
| Eisai INC. | $33.57 | 2025 | |
| Gilead Sciences, INC. | $32.30 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $31.85 | 2019-2020 | |
| Lilly USA, LLC | $26.25 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.79 | 2025 | |
| Pfizer INC. | $19.64 | 2025 | |
| Merck Sharp & Dohme LLC | $19.28 | 2024 | Keytruda |
| Astellas Pharma US INC | $16.78 | 2019 | |
| Glaxosmithkline, LLC. | $16.44 | 2023 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $14.53 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $13.88 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.35 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Morginstin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.